Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Curis Inc (CRIS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Curis Inc Latest News and Headlines for [[ item.sessionDateDisplayLong ]]
Curis Highlights Publication in Nature Cell Biology Identifying Cancer-Causing Form of IRAK4 in Patients with AML and MDS

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today highlighted a publication titled "U2AF1 mutations induce oncogenic...

CRIS : 1.50 (+2.74%)
Curis: 1Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $9.9 million in its first quarter.

CRIS : 1.50 (+2.74%)
Curis Reports First Quarter 2019 Financial Results

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March...

CRIS : 1.50 (+2.74%)
Curis to Release First Quarter Financial Results and Hold Conference Call on May 14, 2019

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter financial...

CRIS : 1.50 (+2.74%)
Curis Completes Mesothelioma Enrollment in CA-170 Study

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Phase 1 study of CA-170 has reached its target...

CRIS : 1.50 (+2.74%)
Healthcare Companies Search for New Ways to Oppose the Spread of Cancer

Cancer is among one of the leading causes of death in the world since many countries are burdened by the lack of access to adequate healthcare, which results in the high number of deaths. In 2018, the...

CRIS : 1.50 (+2.74%)
CVM : 6.12 (+5.15%)
GERN : 1.47 (-1.34%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
NLNK : 1.53 (-1.92%)
Research Report Identifies Denison Mine, Obsidian Energy, Cherry Hill Mortgage Investment, Curis, DASAN Zhone Solutions, and CVD Equipment with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Denison Mine Corp (NYSE:DNN), Obsidian...

CVV : 3.67 (-1.08%)
OBE : 1.11 (+5.71%)
DNN : 0.52 (unch)
CRIS : 1.50 (+2.74%)
DZSI : 12.95 (-0.15%)
CHMI : 16.60 (-0.24%)
Curis Regains Compliance with Nasdaq Continued Listing Requirements

Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it received written confirmation from the Listing...

CRIS : 1.50 (+2.74%)
Curis Announces Advancement to the 200mg BID Cohort in the CA-4948 Study

Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it has begun dosing patients in the 5th cohort...

CRIS : 1.50 (+2.74%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 2, 2019, the independent Compensation...

CRIS : 1.50 (+2.74%)
Curis: 4Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $5.9 million in its fourth quarter.

CRIS : 1.50 (+2.74%)
Curis Reports Fourth Quarter and Year-End 2018 Financial Results

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year...

CRIS : 1.50 (+2.74%)
Thinking about buying stock in Aldeyra Therapeutics, Bed Bath & Beyond Inc., Curis Inc., Cronos Group Inc., or Hunter Maritime Acquisition Corp.?

InvestorsObserver issues critical PriceWatch Alerts for ALDX, BBBY, CRIS, CRON, and HUNT.

CRIS : 1.50 (+2.74%)
BBBY : 11.83 (-2.15%)
HUNTU : 88.00 (+310.45%)
How Leukemia Clinical Trials are Helping Practitioners Personalize Patient Care

At present, medical practitioners have few options when they are presented with a patient with leukemia. The Leukemia & Lymphoma Society's website points out that : "It's important that your doctor is...

CRIS : 1.50 (+2.74%)
GILD : 67.10 (+1.12%)
TEVA : 8.20 (-0.49%)
NK : 1.04 (+1.96%)
MBRX : 1.16 (+0.87%)
Curis Sells Portion of Erivedge Royalties to Oberland Capital for up to $135.7 million

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an agreement with funds managed...

CRIS : 1.50 (+2.74%)
Curis to Release Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 26, 2019

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter and...

CRIS : 1.50 (+2.74%)
Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive...

CRIS : 1.50 (+2.74%)
Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive...

CRIS : 1.50 (+2.74%)
Has Curis (CRIS) Outpaced Other Medical Stocks This Year?

Is (CRIS) Outperforming Other Medical Stocks This Year?

CRIS : 1.50 (+2.74%)
Is Curis (CRIS) Outperforming Other Medical Stocks This Year?

Is (CRIS) Outperforming Other Medical Stocks This Year?

CRIS : 1.50 (+2.74%)

Van Meerten Stock Picks

American Software
My Pick of the Day belongs to the computer software company American Software (AMSWA).
AMSWA +0.28
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar